Biotech and drug-innovation themes continue to dominate markets—from AI-driven drug discovery to blockbuster obesity treatments—and a new ETF filing suggests asset managers want a piece of that ...

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

ARK Invest deployed over $10M in CRISPR Therapeutics and PayPay Corp on March 12, while cutting positions in Teradyne and Ionis Pharmaceuticals.

Tired of seeing drug commercials on TV as health care costs continue to rise? So are advocates, who want to remove a state tax break for pharmaceutical ads, arguing that those funds would be better ...

In this article, we will discuss the 12 Best Get Rich Quick Stocks to Buy According to Hedge Funds. On March 9, Main Management CEO and Portfolio Manager Kim Arthur joined CNBC’s ‘Halftime Report’ to ...

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout ...

Brent crude has crossed the psychologically critical $100 per barrel mark after Iranian strikes on two oil tankers raised fears of supply disruptions through the Strait of Hormuz.

Shares end lower; Electro Optic Systems’ Middle East deal; Dalrymple Bay raises $350m; BHP’s fresh Chinese blow; Immutep sinks on failed test; ANZ warns on Asia energy. Follow live.

New Delhi: A PhD holder in organic chemistry from Medak district in Telangana has come under investigation by anti-drug authorities for allegedly funding his wife's successful gram panchayat election ...

Sydney hedge fund Regal Partners Ltd. was dealt a fresh blow after Immutep Ltd., an Australian biotech company it backs, ...

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.